Page last updated: 2024-12-05

4-hydroxypyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-Hydroxypyridine is a heterocyclic compound that has been the subject of various research studies due to its potential applications in diverse fields. It serves as an intermediate in the synthesis of various pharmaceuticals, agrochemicals, and dyes. Research has shown that 4-hydroxypyridine exhibits diverse biological activities, including anti-inflammatory, analgesic, and antimicrobial properties. Its ability to act as a chelating agent has led to its investigation as a potential treatment for heavy metal poisoning. Notably, 4-hydroxypyridine has also garnered interest as a corrosion inhibitor due to its ability to form protective films on metallic surfaces. The compound has also been explored as a potential precursor for the synthesis of novel materials with intriguing properties. Further research is ongoing to fully understand its pharmacological and industrial applications. '

4-pyridone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-hydroxypyridine : A monohydroxypyridine that is pyridine in which the hydrogen at position 4 has been replaced by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

4-pyridone : The simplest member of the class of pyridin-4-ones, that is 1,4-dihydropyridine in which the hydrogens at position 4 have been replaced by an oxo group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID12290
CHEMBL ID237459
CHEBI ID133125
CHEBI ID87614

Synonyms (83)

Synonym
AC-2927
5-21-07-00152 (beilstein handbook reference)
nsc-5080
4-pyridinol
4-hydroxypyridine
nsc5080
626-64-2
.gamma.-hydroxypyridine
gamma-hydroxypyridine
pyridin-4-ol
AC-907/34116018
einecs 210-958-3
brn 0105800
nsc 5080
ai3-61970
inchi=1/c5h5no/c7-5-1-3-6-4-2-5/h1-4h,(h,6,7
pyridin-4(1h)-one
nsc-146174
4(1h)-pyridone
nsc146174
4-oxopyridine
4(1h)-pyridinone
4-pyridone
4-pyridinone
108-96-3
.gamma.-pyridone
4-hydroxypyridine, 95%
1h-pyridin-4-one
C1201
pyridin-4-one
gamma-pyridone
CHEBI:133125
A1E9A648-09AC-4FC9-A7AF-37534D102469
CHEMBL237459
sr-1c7
H0332
AKOS000121024
A8662
unii-3p2mv07g53
einecs 203-633-2
nsc 146174
3p2mv07g53 ,
einecs 222-380-9
FT-0618744
FT-0618743
AM20061387
PB17041
smr003288679
MLS004491722
BBL022970
STL363251
AKOS022377006
4-hydroxypridine
p-hydroxypyridine
4-hydroxy-pyridine
1,4-dihydro-4-pyridinone
dtxsid2052310 ,
tox21_303817
NCGC00357095-01
dtxcid9030882
cas-626-64-2
W-104968
BS-3730
STR01041
4-pyridol
hydroxypyridine, 4-
mfcd00040458
butanoic acid,heptafluoro-,1,10-decanediyl ester(9ci)
CHEBI:87614
CS-W007690
4-hydroxypyridine, aldrichcpr
mfcd00006419
SY003367
Q230024
BCP08909
cqg ,
D82355
SB52275
CS-0166783
1,4-dihydropyridin-4-one
EN300-21574
HY-W007690
SY112252

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" In general, the most potent 4-pyridones are lipophilic molecules with poor solubility in aqueous media and low oral bioavailability in pre-clinical species from the solid dosage form."( Potent antimalarial 4-pyridones with improved physico-chemical properties.
Bueno, JM; Chicharro, J; Ferrer, S; Fiandor, JM; Fraile, MT; García, A; García, MC; Gargallo-Viola, D; Gómez, RM; Herreros, E; Lavandera, JL; Lorenzo, M; Manzano, P; Puente, M; Vidal, J, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" In general, the most potent 4-pyridones are lipophilic molecules with poor solubility in aqueous media and low oral bioavailability in pre-clinical species from the solid dosage form."( Potent antimalarial 4-pyridones with improved physico-chemical properties.
Bueno, JM; Chicharro, J; Ferrer, S; Fiandor, JM; Fraile, MT; García, A; García, MC; Gargallo-Viola, D; Gómez, RM; Herreros, E; Lavandera, JL; Lorenzo, M; Manzano, P; Puente, M; Vidal, J, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
monohydroxypyridineA hydroxypyridine carrying a single hydroxy substituent.
4-pyridonesAny pyridone that is pyridin-4-one or its derivatives by substitution of one of more of the hydrogens.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency10.87070.001530.607315,848.9004AID1224841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID303044Cytotoxicity against human MIA PaCa2 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.
AID303043Cytotoxicity against human MIA PaCa2 cells after 4 hrs by MTT assay2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (24.39)18.7374
1990's2 (4.88)18.2507
2000's10 (24.39)29.6817
2010's15 (36.59)24.3611
2020's4 (9.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.54 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index43.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other41 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]